Clinical Trials Logo

Nephritis clinical trials

View clinical trials related to Nephritis.

Filter by:

NCT ID: NCT01226147 Recruiting - Lupus Nephritis Clinical Trials

Efficacy and Safety of Tamibarotene(AM80) for Lupus Nephritis

Start date: September 2010
Phase: Phase 2
Study type: Interventional

An open-label study to evaluate the efficacy and safety of orally administered Tamibarotene to patients of Lupus Nephritis

NCT ID: NCT01207297 Completed - Clinical trials for End-stage Renal Disease

Tacrolimus Versus Cyclophosphamide as Treatment for Lupus Nephritis

Start date: March 2003
Phase: Phase 1
Study type: Interventional

In this comparative open-label cohort study, the investigators compared the efficacy and safety of tacrolimus (TAC)and cyclophosphamide (CYC) in the treatment of diffuse proliferative and membranous lupus nephritis with severe renal disease. Treatment of lupus nephritis (LN) with cyclophosphamide is effective, but retain a certain proportion of renal function exacerbations. Tacrolimus may be a suitable substitute treatment for CYC. Methods: Forty patients with diffuse proliferative or membranous were recruited for this trial, 45% of them had lower Ccr (<60mL/min/1.73m2), 10% had increased serum creatinine (>180µmol/L) and 67.5% had nephritic proteinuria (>3.5g/day). The investigators compared the efficacy and adverse effects of TAC (0.04-0.08 mg/kg/d) and prednisone for 12 months (TAC group) with pulse cyclophosphamide (750mg/m2 per month for six months) and prednisone followed by azathioprine (50mg/day)for 6 months (CYC group).

NCT ID: NCT01206569 Completed - Lupus Nephritis Clinical Trials

Long-Acting Tacrolimus for the Treatment of Resistant Lupus Nephritis

Start date: September 2010
Phase: Phase 4
Study type: Interventional

Glomerulonephritis is one of the major disease manifestations of systemic lupus erythematosus (SLE). Around one-third of the patients, however, do not respond to conventional immunosuppressive therapy, and they have a high risk of progressing to dialysis-dependent renal failure. Recent studies suggest that immunosuppressive therapy targeted against the calcineurin pathway of T-helper cell, for example, tacrolimus, may be effective in the treatment of primary glomerulonephritis. The investigators plan to an open-label single-arm study the efficacy and safety of long-acting tacrolimus in the treatment of treatment-resistant lupus nephritis. Twenty-five patients with biopsy-proven lupus nephritis will be recruited. They will be treated with oral prednisolone and long-acting tacrolimus for 6 months, followed by 6 months of maintenance steroid and azathioprine. Proteinuria, renal function, clinical and serologic lupus activity will be monitored. This study will explore the potential role of long-acting tacrolimus in resistant lupus nephritis, which has a poor prognosis and no effective treatment at the moment.

NCT ID: NCT01203709 Completed - Lupus Nephritis Clinical Trials

Low-dose Combination of Mycophenolate Mofetil (MMF) and Tacrolimus (Tac) for Refractory Lupus Nephritis

Start date: August 2010
Phase: Phase 4
Study type: Interventional

A trial of combination of two drugs for the treatment of refractory lupus nephritis.

NCT ID: NCT01172002 Recruiting - Lupus Clinical Trials

Leflunomide Versus Azathioprine for Maintenance Therapy of Lupus Nephritis

Start date: March 2010
Phase: N/A
Study type: Interventional

Leflunomide versus Azathioprine for Maintenance Therapy of Lupus Nephritis

NCT ID: NCT01169857 Withdrawn - Lupus Nephritis Clinical Trials

Velcade for Proliferative Lupus Nephritis

Start date: August 2010
Phase: Phase 4
Study type: Interventional

The primary objective is to test the safety and efficacy of Velcade to induce remission in WHO class III/IV/V lupus nephritis that are refractory to standard medications.

NCT ID: NCT01085097 Completed - Lupus Nephritis Clinical Trials

A Study of Laquinimod in Participants With Systemic Lupus Erythematosus (SLE) Active Lupus Nephritis

Start date: September 1, 2010
Phase: Phase 2
Study type: Interventional

The study aims to evaluate the safety and clinical effect of daily oral treatment with laquinimod capsules in active lupus nephritis participants. This study will assess Laquinimod doses of 0.5 milligrams (mg)/day and 1 mg/day in combination with standard of care treatment (mycophenolate mofetil [MMF] and corticosteroids). Laquinimod is a novel immunomodulating drug which is currently in advanced stages of development by Teva Pharmaceuticals Ltd. for Multiple Sclerosis.

NCT ID: NCT01056237 Completed - Lupus Nephritis Clinical Trials

Long-Term Study of Multi-target Therapy as Maintenance Treatment for Lupus Nephritis

Start date: February 2010
Phase: N/A
Study type: Interventional

An multi-site, randomized, prospective study to compare the efficacy and safety of multi-target therapy as continuous induction and maintenance treatment versus CTX- Aza therapy.

NCT ID: NCT01042457 Completed - Lupus Nephritis Clinical Trials

Concentration-controlled Therapy of Mycophenolate Mofetil (MMF) in Proliferative Lupus Nephritis

Start date: May 2009
Phase: Phase 3
Study type: Interventional

To evaluate therapeutic response to MMF treatment in patients with International Society of Nephrology/Renal Pathology Society (ISN/RPS) class III or IV lupus nephritis. Mycophenolic acid levels at 1-hour post dose will be monitored monthly up to 6 months.

NCT ID: NCT01015456 Terminated - Lupus Nephritis Clinical Trials

The Efficacy of Enteric-coated Mycophenolate Sodium (EC-MPS) (Myfortic) in The Treatment of Relapse or Resistant Proliferative Lupus Nephritis

CONTROL
Start date: January 2010
Phase: Phase 3
Study type: Interventional

To investigate the efficacy and safety of enteric-coated mycophenolate sodium (Myfortic) as compared to intravenous cyclophosphamide in the treatment of active nephritis. The primary outcomes are complete and partial renal remission, as assessed by renal function, urinary sediment and proteinuria in patients with International Society of Nephrology/ Renal Pathology Society (ISN/RPS) class III or IV lupus nephritis.